Ranee Mehra

16.1k total citations · 4 hit papers
194 papers, 6.5k citations indexed

About

Ranee Mehra is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Ranee Mehra has authored 194 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Oncology, 102 papers in Pulmonary and Respiratory Medicine and 86 papers in Otorhinolaryngology. Recurrent topics in Ranee Mehra's work include Head and Neck Cancer Studies (86 papers), Lung Cancer Treatments and Mutations (81 papers) and Cancer Immunotherapy and Biomarkers (45 papers). Ranee Mehra is often cited by papers focused on Head and Neck Cancer Studies (86 papers), Lung Cancer Treatments and Mutations (81 papers) and Cancer Immunotherapy and Biomarkers (45 papers). Ranee Mehra collaborates with scholars based in United States, South Korea and Italy. Ranee Mehra's co-authors include Barbara Burtness, Laura Q.M. Chow, Tanguy Y. Seiwert, Jonathan D. Cheng, Joseph P. Eder, Jared Weiss, John A. Ridge, Karl Heath, Raanan Berger and Jared Lunceford and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ranee Mehra

187 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

2016 1.3k citations Tanguy Y. Seiwert, Barbara Burtness et al. profile →
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

2011 445 citations Arlene A. Forastiere, Roger B. Cohen et al. Journal of Clinical Oncology profile →
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

2018 329 citations Ranee Mehra, Tanguy Y. Seiwert et al. profile →
Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States

2015 298 citations Thomas J. Galloway, Ranee Mehra et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Ranee Mehra

Since Specialization

Citations

This map shows the geographic impact of Ranee Mehra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ranee Mehra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ranee Mehra more than expected).

Fields of papers citing papers by Ranee Mehra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ranee Mehra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ranee Mehra. The network helps show where Ranee Mehra may publish in the future.

Co-authorship network of co-authors of Ranee Mehra

This figure shows the co-authorship network connecting the top 25 collaborators of Ranee Mehra. A scholar is included among the top collaborators of Ranee Mehra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ranee Mehra. Ranee Mehra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck 2025 ·Head & Neck ·Aarti Bhatia, Ranee Mehra, Jessica R. Bauman, Saad A. Khan, Wei Wei, Veronique Neumeister, Teresa Sandoval-Schaefer, R. Katherine Alpaugh, Miriam N. Lango, David L. Rimm, John A. Ridge, Barbara Burtness	2
2	Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer 2025 ·Journal of Clinical Oncology ·Barbara Burtness, Yael Flamand, Harry Quon, Gregory S. Weinstein, Ranee Mehra, (unknown), Seungwon Kim, Bert W. O’Malley, Enver Özer, Chukwuemeka Ikpeazu, Wayne M. Koch, Neil D. Gross, R. Bryan Bell, Mihir R. Patel, Miriam N. Lango, Luc G.T. Morris, Russell K. Smith, Daniel W. Karakla, Jeremy D. Richmon, F. Christopher Holsinger, Robert L. Ferris	4
3	Overall survival after treatment with CAN-2409 plus valacyclovir in combination with continued ICI in patients with stage III/IV NSCLC with an inadequate response to ICI. 2024 ·Journal of Clinical Oncology ·Charu Aggarwal, Daniel H. Sterman, Erin R. Alesi, Fabien Maldonado, Ranee Mehra, Christine M. Bestvina, Janani Reisenauer, (unknown), Sonam Puri, Omar M. Ibrahim, George A. Eapen, Caroline Duault, (unknown), Diane M. Del Valle, Edgar Gonzalez‐Kozlova, Sacha Gnjatic, Holden T. Maecker, (unknown), Francesca Barone, Paul P. Tak	6
4	A phase I monotherapy dose escalation study of HFB301001, a novel next generation OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Anthony B. El-Khoueiry, Elena Garralda, Andrés Cervantes, Candace L. Haddox, Hani M. Babiker, Mitesh J. Borad, Konstantinos Leventakos, Ranee Mehra, Jon Zugazagoitia, Diana L. Hanna, Guzmán Alonso, Angela Liu, Xiaorong Shi, (unknown), (unknown), William D. Hedrich, (unknown), (unknown), (unknown), Robert H.I. Andtbacka	1
5	Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group. 2024 ·Journal of Clinical Oncology ·Barbara Burtness, Yael Flamand, Harry Quon, Gregory S. Weinstein, Ranee Mehra, Joaquín J. García, Seungwon Kim, Bert W. O’Malley, Enver Özer, Wayne M. Koch, Neil D. Gross, R. Bryan Bell, Mihir R. Patel, Miriam N. Lango, (unknown), Russell K. Smith, Daniel W. Karakla, Jeremy D. Richmon, F. Christopher Holsinger, Robert L. Ferris	4
6	Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy 2023 ·Journal for ImmunoTherapy of Cancer ·Naiyer A. Rizvi, Foluso O. Ademuyiwa, Z. Alexander Cao, Helen X Chen, Robert L. Ferris, Sarah B. Goldberg, Matthew D. Hellmann, Ranee Mehra, Ina Rhee, Jong Chul Park, Harriet M. Kluger, Hussein A. Tawbi, Ryan J. Sullivan	24
7	Regionalization of Head and Neck Oncology Tumor Boards: Perspectives of Collaborating Physicians 2023 ·OTO Open ·(unknown), (unknown), Jessica Brown, (unknown), Rodney J. Taylor, Jeffrey S. Wolf, Matthew E. Witek, Jason K. Molitoris, Ranee Mehra, Kevin J. Cullen, John C. Papadimitriou, Prashant Raghavan, Kyle M. Hatten	2
8	Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment 2022 ·SHILAP Revista de lepidopterología ·Candice Yong, M. Janelle Cambron‐Mellott, Brian Seal, (unknown), (unknown), (unknown), (unknown), Ion Cotarla, Ranee Mehra	7
9	Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma 2022 ·Oral Oncology ·Zejia Yang, Jipei Liao, Lisa M. Schumaker, Brandon Carter‐Cooper, Rena G. Lapidus, Xiaoxuan Fan, Daria A. Gaykalova, Ranee Mehra, Kevin J. Cullen, Hancai Dan	8
10	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma 2022 ·Journal for ImmunoTherapy of Cancer ·Robert I. Haddad, Tanguy Y. Seiwert, Laura Q.M. Chow, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Andrew Albright, Robin Mogg, Mark Ayers, Lingkang Huang, Jared Lunceford, Răzvan Cristescu, Jonathan D. Cheng, Ranee Mehra	54
11	Treatment modalities, adverse events, and survival outcomes in older patients with head and neck squamous cell carcinoma 2021 ·Head & Neck ·Sania Amr, (unknown), (unknown), Ranee Mehra, Kevin J. Cullen, Olga Goloubeva	4
12	Comparison of efficacy and toxicity of chemoradiation regimens for head and neck squamous cell carcinoma primary treatment 2021 ·Head & Neck ·Michael G. McCusker, Ranee Mehra, Sania Amr, Rodney J. Taylor, Kevin J. Cullen, Olga Goloubeva	3
13	Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication 2020 ·Clinical Cancer Research ·Jared Weiss, Siddharth Sheth, Allison M. Deal, Juneko E. Grilley‐Olson, Samip Patel, Trevor Hackman, Jeffrey M. Blumberg, Thomas J. Galloway, Shetal Patel, Adam M. Zanation, Colette J. Shen, D. Neil Hayes, Christopher Hilliard, Ranee Mehra, Karen P. McKinnon, Hsing‐Hui Wang, Mark C. Weissler, Jessica R. Bauman, Bhishamjit S. Chera, Benjamin G. Vincent	29
14	Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck 2019 ·Clinical Cancer Research ·Jong Woo Lee, (unknown), Teresa Sandoval-Schaefer, Kyung Jin Eoh, Dong‐Hua Yang, Fang Zhu, Ranee Mehra, Roshan Sharma, Stephen G. Gaffney, Elizabeth B. Perry, Jeffrey P. Townsend, Ilya G. Serebriiskii, Erica A. Golemis, Natalia Issaeva, Wendell G. Yarbrough, Ja Seok Koo, Barbara Burtness	58
15	Long-Term Toxicities in Survivors of Radiation Treatment for Head and Neck Cancer 2016 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), T.M. Churilla, Ranee Mehra, Miriam N. Lango, Jessica R. Bauman, John A. Ridge, Thomas J. Galloway	0
16	Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303 2014 ·Clinical Cancer Research ·Ann Marie Egloff, Ju-Whei Lee, Corey J. Langer, Harry Quon, Alec Vaezi, Jennifer R. Grandis, Raja R. Seethala, Lin Wang, Dong M. Shin, Athanassios Argiris, Dong‐Hua Yang, Ranee Mehra, John A. Ridge, Urjeet A. Patel, Barbara Burtness, Arlene A. Forastiere	26
17	Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers 2013 ·Clinical Cancer Research ·Ranee Mehra, Fang Zhu, Dong‐Hua Yang, Kathy Q. Cai, JoEllen Weaver, Mahendra Singh, Anna S. Nikonova, Erica A. Golemis, Douglas B. Flieder, Harry S. Cooper, Miriam N. Lango, John A. Ridge, Barbara Burtness	21
18	Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements 2012 ·Clinical Cancer Research ·D. Neil Hayes, (unknown), Tawee Tanvetyanon, Monika K. Krzyzanowska, Christine H. Chung, Barbara A. Murphy, Jill Gilbert, Ranee Mehra, Dominic T. Moore, Arif Sheikh, Janelle M. Hoskins, Michele C. Hayward, Ni Zhao, (unknown), Karen E. Weck, Roger B. Cohen, Ezra E.W. Cohen	120
19	The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer 2010 ·SHILAP Revista de lepidopterología ·Mohamedtaki Abdulaziz Tejani, Roger B. Cohen, Ranee Mehra	8
20	Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials 2006 ·Expert Opinion on Biological Therapy ·Ranee Mehra, Barbara Burtness	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact